Federal Register #DEA1724

DEA Solicitation for Importation of Controlled Substances for Research and Analytical Use

This opportunity involves the Drug Enforcement Administration (DEA) considering applications from several organizations to import controlled substances for clinical research and analytical purposes. - Government Buyer: - Department of Justice, Drug Enforcement Administration (DEA), Importer of Controlled Substances office - OEMs and Vendors Mentioned: - AndersonBrecon, Inc. DBA PCI Pharma Services - Arizona Department of Corrections - Scottsdale Research Institute - Veranova, L.P. - Products/Services Requested: - Importation of bulk Active Pharmaceutical Ingredients (APIs) and analytical reference standards for controlled substances, including: - Tetrahydrocannabinols (part number 7260) - 3,4-Methylenedioxymethamphetamine (part number 7370) - Dimethyltryptamine (part number 7405) - Pentobarbital (part number 2270) - Ibogaine (part number 7260) - Marihuana (synthetic cannabidiol, part number 7360) - Coca Leaves (part number 9040) - Thebaine (part number 9333) - Opium, Raw (part number 9600) - Noroxymorphone (part number 9668) - Poppy Straw Concentrate (part number 9670) - Fentanyl (part number 9801) - Unique or Notable Requirements: - All imports are strictly for use as bulk APIs or analytical reference standards to support clinical research or legitimate institutional needs - No authorization is granted for importing finished dosage forms for commercial sale - Applications are open for public comment and potential hearing requests - Each applicant is limited to the substances and purposes specified in their application

Description

Scottsdale Research Institute has applied to be registered as an importer of basic classes of controlled substances including Ibogaine, Marihuana, and 3,4-Methylenedioxymethamphetamine. The company plans to import these substances as bulk Active Pharmaceutical Ingredients to support clinical research by Schedule I registrants. The application specifies that no other activities for these drug codes are authorized under this registration. Comments and objections to the issuance of the proposed registration are due by July 17, 2026, and a hearing may be requested by that date.

View original listing